That's according to a new study presented this week in Nice, France, at the annual meeting of the European Research Organization on Genital Infection and Neoplasia (EUROGIN).
The new study included 4,065 men aged 16-26. They got three shots of Gardasil or a placebo over six months.
Participants who got the Gardasil shots were 90% less likely to develop genital warts related to the four HPV strains that Gardasil targets.
No serious side effects were linked to Gardasil, though participants who got Gardasil reported "slightly more" injection site reactions than participants in the placebo group, according to the researchers, who included Joel Palefsky, MD, of the University of California at San Francisco.
Merck, the drug company that makes Gardasil, funded the study.
The FDA hasn't approved Gardasil for use in boys or men. Merck plans to file an application this year asking the FDA to approve Gardasil for boys and men aged 9 to 26 to prevent genital warts.